Toshihiko Kobayashi

Toshihiko Kobayashi

Auto-generated profile, based on publicly available information

Toshihiko Kobayashi

Department of Molecular Immunology and Inflammation, Research Institute, National Center for Global Health and Medicine, Tokyo 162-8655, Japan

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2014 in Immunity
Verified
Journal Article
Closed access
TKToshihiko Kobayashi
Toshihiko Kobayashi
SSShiho Shimabukuro-Demoto
Shiho Shimabukuro-Demoto
RYReiko Yoshida-Sugitani
Reiko Yoshida-Sugitani
KFKaori Furuyama-Tanaka
Kaori Furuyama-Tanaka
HKHitomi Karyu
Hitomi Karyu
NTNoriko Toyama-Sorimachi
Noriko Toyama-Sorimachi

12 August 2021 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
TKToshihiko Kobayashi
Toshihiko Kobayashi
DNDat Nguyen-Tien
Dat Nguyen-Tien
YSYuriko Sorimachi
Yuriko Sorimachi
Yuki SugiuraYuki Sugiura
Yuki Sugiura
TSTakehiro Suzuki
Takehiro Suzuki
NTNoriko Toyama-Sorimachi
Noriko Toyama-Sorimachi
Significance: SLC15A4 is a lysosome-resident amino acid/oligopeptide transporter that is preferentially expressed in immune cells. SLC15A4 is required for TLR7/9-dependent type I interferon production and plays a critical role in the pathogenesis of lupus and colitis. However, the precise molecular mechanisms of SLC15A4-mediated inflammatory responses are still undetermined. We revealed that SLC15A4 loss disturbed the coupling of glycolysis and the TCA cycle, and SLC15A4-deficient macrophages preferred to use glutamine rather than glucose as a carbon source for the TCA cycle. SLC15A4-deficient macrophages produced low levels of itaconate and proinflammatory IL-12 cytokine members. Our results reveal a mechanism of metabolic regulation in which an amino acid transporter acts as a guardian to allow macrophages to acquire an M1-prone metabolic phenotype.

15 November 2019 in PLOS Biology
Verified
Journal Article
Open access
PDF file
TKToshihiko Kobayashi
Toshihiko Kobayashi
SSShiho Shimabukuro-Demoto
Shiho Shimabukuro-Demoto
HTHidemitsu Tsutsui
Hidemitsu Tsutsui
NTNoriko Toyama-Sorimachi
Noriko Toyama-Sorimachi
Type I interferon (IFN-I) is a family of multifunctional cytokines that modulate the innate and adaptive immunity and are used to treat mastocytosis. Although IFN-I is known to suppress mast cell function, including histamine release, the mechanisms behind its effects on mast cells have been poorly understood. We here investigated IFN-I’s action on mast cells using interferon-α/β receptor subunit 1 (Ifnar1)-deficient mice, which lack a functional IFN-I receptor complex, and revealed that IFN-I in the steady state is critical for mast cell homeostasis, the disruption of which is centrally involved in systemic anaphylaxis. Ifnar1-deficient mice showed exacerbated systemic anaphylaxis after sensitization, which was associated with increased histamine in the circulation, even though the mast cell numbers and high affinity immunoglobulin E receptor (FcεRI) expression levels were similar between Ifnar1-deficient and wild-type (WT) mice. Ifnar1-deficient mast cells showed increased secretory granule synthesis and exocytosis, which probably involved the increased transcription of Tfeb. Signal transducer and activator of transcription 1(Stat1) and Stat2 were unexpectedly insufficient to mediate these IFN-I functions, and instead, Stat3 played a critical role in a redundant manner with Stat1. Our findings revealed a novel regulation mechanism of mast cell homeostasis, in which IFN-I controls lysosome-related organelle biogenesis.

1 January 2015 in Bio-Protocol
Verified
Journal Article
Closed access
TKToshihiko Kobayashi
Toshihiko Kobayashi
TTTsubasa Tanaka
Tsubasa Tanaka
NTNoriko Toyama-Sorimachi
Noriko Toyama-Sorimachi

1 December 2013
Verified
Journal Article
Closed access
TTTsubasa Tanaka
Tsubasa Tanaka
TKToshihiko Kobayashi
Toshihiko Kobayashi
NTNoriko Toyama-Sorimachi
Noriko Toyama-Sorimachi